{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:38:04Z","timestamp":1791315484224,"version":"4.3.1"},"reference-count":35,"publisher":"American Association for Cancer Research (AACR)","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"vor","delay-in-days":100,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"\u201cJian Bing Ling Yan + X\u201d R&D program of Zhejiang Province","award":["2025SDXT002-2 and 2026C02A1108"],"award-info":[{"award-number":["2025SDXT002-2 and 2026C02A1108"]}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2024M763334"],"award-info":[{"award-number":["2024M763334"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82271876"],"award-info":[{"award-number":["82271876"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Strategic Priority Research Program of the Chinese Academy of Science","award":["XDB1020000"],"award-info":[{"award-number":["XDB1020000"]}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>KRAS G12D is the most prevalent subtype of KRAS mutation across solid tumors, but no drug is available in the clinic. RNK08954 is a potent and selective KRASG12D inhibitor that inhibits proliferation of KRASG12D-mutant cells and demonstrates significant tumor regressions in mouse xenograft models while inhibiting KRAS-mediated signaling. The in vivo effects of RNK08954 are explained by its unique pharmacokinetic (PK) profile and significantly prolonged retention time in tumor tissues. RNK08954 shows synergy with immune checkpoint blockade (ICB). In a phase Ia study, the median follow-up was 4.85 months for 36 evaluable patients. In patients with non\u2013small cell lung cancer (NSCLC), the objective response rate (ORR; unconfirmed) was 58.33%, and in patients with pancreatic ductal adenocarcinoma (PDAC), the ORR (unconfirmed) was 33.33% in the 1,000- to 1,200-mg cohort. This study supports the clinical potential of RNK08954 in patients with KRASG12D mutation either as a single agent or in combination.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>RNK08954 is potentially the first orally bioavailable KRASG12D inhibitor, distinguished by unique PK properties, preclinical efficacy, preliminary clinical activity with encouraging results in patients with NSCLC and PDAC, and synergistic potential with ICB. RNK08954 may address a critical unmet need by targeting the most prevalent KRAS mutation across solid tumors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2159-8290.cd-25-1346","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T21:09:06Z","timestamp":1768943346000},"page":"895-910","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Preclinical Characterization and Clinical Activity of RNK08954, a Highly Selective and Orally Bioavailable\n                    <i>KRAS<\/i>\n                    G12D Inhibitor"],"prefix":"10.1158","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7261-1252","authenticated-orcid":false,"given":"Ling","family":"Xie","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0144s0951","id-type":"ROR","asserted-by":"publisher"}],"name":"Zhejiang Cancer Hospital 1 Phase I Clinical Trial Ward, , Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China."},{"name":"2Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9021-6731","authenticated-orcid":false,"given":"Chunwei","family":"Xu","sequence":"additional","affiliation":[{"name":"2Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1646-9524","authenticated-orcid":false,"given":"Han","family":"Si","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0144s0951","id-type":"ROR","asserted-by":"publisher"}],"name":"Zhejiang Cancer Hospital 1 Phase I Clinical Trial Ward, , Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1776-5391","authenticated-orcid":false,"given":"Xiaoshuang","family":"Fu","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0144s0951","id-type":"ROR","asserted-by":"publisher"}],"name":"Zhejiang Cancer Hospital 1 Phase I Clinical Trial Ward, , Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3378-4262","authenticated-orcid":false,"given":"Xiangcai","family":"Yang","sequence":"additional","affiliation":[{"name":"3Ranok Therapeutics (Hangzhou), Inc., Hangzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9903-9276","authenticated-orcid":false,"given":"Jianan","family":"Jin","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0144s0951","id-type":"ROR","asserted-by":"publisher"}],"name":"Zhejiang Cancer Hospital 1 Phase I Clinical Trial Ward, , Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8809-2111","authenticated-orcid":false,"given":"Xiaoqing","family":"Yu","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0144s0951","id-type":"ROR","asserted-by":"publisher"}],"name":"Zhejiang Cancer Hospital 1 Phase I Clinical Trial Ward, , Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5944-0439","authenticated-orcid":false,"given":"Zhiying","family":"Shao","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0144s0951","id-type":"ROR","asserted-by":"publisher"}],"name":"Zhejiang Cancer Hospital 1 Phase I Clinical Trial Ward, , Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9608-5827","authenticated-orcid":false,"given":"Yanling","family":"Wang","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0144s0951","id-type":"ROR","asserted-by":"publisher"}],"name":"Zhejiang Cancer Hospital 1 Phase I Clinical Trial Ward, , Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0744-0397","authenticated-orcid":false,"given":"Tianqing","family":"Chu","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03fjc3817","id-type":"ROR","asserted-by":"publisher"}],"name":"Shanghai Chest Hospital 4 Department of Respiratory and Critical Care Medicine, , School of Medicine, Shanghai Jiao Tong University, Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7973-8416","authenticated-orcid":false,"given":"Jun","family":"Zhang","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01hv94n30","id-type":"ROR","asserted-by":"publisher"}],"name":"Ruijin Hospital 5 Department of Oncology, , Shanghai Jiao Tong University School of Medicine, Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0343-3277","authenticated-orcid":false,"given":"Rong","family":"Liang","sequence":"additional","affiliation":[{"name":"6Affiliated Cancer Hospital of Guangxi Medical University, Nanning, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3090-3473","authenticated-orcid":false,"given":"Rui","family":"Meng","sequence":"additional","affiliation":[{"name":"7Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7137-5625","authenticated-orcid":false,"given":"Yuchen","family":"Fei","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0144s0951","id-type":"ROR","asserted-by":"publisher"}],"name":"Zhejiang Cancer Hospital 1 Phase I Clinical Trial Ward, , Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3645-6501","authenticated-orcid":false,"given":"Haolin","family":"Song","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0144s0951","id-type":"ROR","asserted-by":"publisher"}],"name":"Zhejiang Cancer Hospital 1 Phase I Clinical Trial Ward, , Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6711-5737","authenticated-orcid":false,"given":"Chenghao","family":"Ying","sequence":"additional","affiliation":[{"name":"3Ranok Therapeutics (Hangzhou), Inc., Hangzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2931-9983","authenticated-orcid":false,"given":"Yan","family":"Dai","sequence":"additional","affiliation":[{"name":"3Ranok Therapeutics (Hangzhou), Inc., Hangzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6438-0933","authenticated-orcid":false,"given":"Yaya","family":"Wang","sequence":"additional","affiliation":[{"name":"3Ranok Therapeutics (Hangzhou), Inc., Hangzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0110-6654","authenticated-orcid":false,"given":"Iman","family":"EI-Hariry","sequence":"additional","affiliation":[{"name":"3Ranok Therapeutics (Hangzhou), Inc., Hangzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1626-6308","authenticated-orcid":false,"given":"Guoqiang","family":"Wang","sequence":"additional","affiliation":[{"name":"3Ranok Therapeutics (Hangzhou), Inc., Hangzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5879-3782","authenticated-orcid":false,"given":"Weiwen","family":"Ying","sequence":"additional","affiliation":[{"name":"3Ranok Therapeutics (Hangzhou), Inc., Hangzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2226-0570","authenticated-orcid":false,"given":"Zhengbo","family":"Song","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0144s0951","id-type":"ROR","asserted-by":"publisher"}],"name":"Zhejiang Cancer Hospital 1 Phase I Clinical Trial Ward, , Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China."},{"name":"2Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,1,21]]},"reference":[{"key":"2026050103132342700_bib1","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1158\/2159-8290.CD-21-1331","article-title":"Expanding the reach of precision oncology by drugging all KRAS mutants","volume":"12","author":"Hofmann","year":"2022","journal-title":"Cancer Discov"},{"key":"2026050103132342700_bib2","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1146\/annurev-cancerbio-050216-122010","article-title":"Targeting KRAS directly","volume":"2","author":"McCormick","year":"2018","journal-title":"Annu Rev Canc Biol"},{"key":"2026050103132342700_bib3","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1038\/s41467-021-22125-z","article-title":"The origins and genetic interactions of KRAS mutations are allele- and tissue-specific","volume":"12","author":"Cook","year":"2021","journal-title":"Nat Commun"},{"key":"2026050103132342700_bib4","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.trecan.2023.07.010","article-title":"Next batter up! Targeting cancers with KRAS-G12D mutations","volume":"9","author":"Zeissig","year":"2023","journal-title":"Trends Cancer"},{"key":"2026050103132342700_bib5","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41698-022-00334-z","article-title":"Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors","volume":"6","author":"Lee","year":"2022","journal-title":"NPJ Precis Oncol"},{"key":"2026050103132342700_bib6","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41698-024-00505-0","article-title":"Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma","volume":"8","author":"Yousef","year":"2024","journal-title":"NPJ Precis Oncol"},{"key":"2026050103132342700_bib7","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1158\/1078-0432.CCR-23-2098","article-title":"A small molecule with big impact: MRTX1133 targets the KRASG12D mutation in pancreatic cancer","volume":"30","author":"Wei","year":"2024","journal-title":"Clin Cancer Res"},{"key":"2026050103132342700_bib8","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1172\/JCI59227","article-title":"Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice","volume":"122","author":"Collins","year":"2012","journal-title":"J Clin Invest"},{"key":"2026050103132342700_bib9","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1038\/s41467-017-01519-y","article-title":"Multiplexed in vivo homology-directed repair and tumor barcoding enables parallel quantification of Kras variant oncogenicity","volume":"8","author":"Winters","year":"2017","journal-title":"Nat Commun"},{"key":"2026050103132342700_bib10","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1158\/1535-7163.MCT-21-0201","article-title":"Characterization of KRAS mutation subtypes in non-small cell lung cancer","volume":"20","author":"Judd","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"2026050103132342700_bib11","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1158\/0008-5472.CAN-17-3303","article-title":"Combined mutation of Apc, Kras, and Tgfbr2 effectively drives metastasis of intestinal cancer","volume":"78","author":"Sakai","year":"2018","journal-title":"Cancer Res"},{"key":"2026050103132342700_bib12","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1038\/nm.3967","article-title":"The consensus molecular subtypes of colorectal cancer","volume":"21","author":"Guinney","year":"2015","journal-title":"Nat Med"},{"key":"2026050103132342700_bib13","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.gendis.2021.08.011","article-title":"Covalent inhibitor targets KRasG12C: a new paradigm for drugging the undruggable and challenges ahead","volume":"10","author":"Li","year":"2023","journal-title":"Genes Dis"},{"key":"2026050103132342700_bib14","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa2204619","article-title":"Adagrasib in non-small-cell lung cancer harboring a KRASG12C mutation","volume":"387","author":"J\u00e4nne","year":"2022","journal-title":"N Engl J Med"},{"key":"2026050103132342700_bib15","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","article-title":"Sotorasib for lung cancers with KRAS p.G12C mutation","volume":"384","author":"Skoulidis","year":"2021","journal-title":"N Engl J Med"},{"key":"2026050103132342700_bib16","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1056\/NEJMoa2303810","article-title":"Single-agent divarasib (GDC-6036) in solid tumors with a KRAS G12C mutation","volume":"389","author":"Sacher","year":"2023","journal-title":"N Engl J Med"},{"key":"2026050103132342700_bib17","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1038\/s41591-022-02007-7","article-title":"Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor","volume":"28","author":"Hallin","year":"2022","journal-title":"Nat Med"},{"key":"2026050103132342700_bib18","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.ccell.2024.06.001","article-title":"Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer","volume":"42","author":"Zhou","year":"2024","journal-title":"Cancer Cell"},{"key":"2026050103132342700_bib19","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1021\/acs.jmedchem.4c02662","article-title":"Discovery of INCB159020, an orally bioavailable KRAS G12D inhibitor","volume":"68","author":"Ye","year":"2025","journal-title":"J Med Chem"},{"key":"2026050103132342700_bib20","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1021\/acs.jmedchem.1c01688","article-title":"Identification of MRTX1133, a noncovalent, potent, and selective KRASG12D inhibitor","volume":"65","author":"Wang","year":"2022","journal-title":"J Med Chem"},{"key":"2026050103132342700_bib21","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41421-021-00368-w","article-title":"KRASG12D can be targeted by potent inhibitors via formation of salt bridge","volume":"8","author":"Mao","year":"2022","journal-title":"Cell Discov"},{"key":"2026050103132342700_bib22","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/S0959-8049(22)00881-4","article-title":"85 (PB075) - ASP3082, a First-in-class novel KRAS G12D degrader, exhibits remarkable anti-tumor activity in KRAS G12D mutated cancer models","volume":"174","author":"Nagashima","year":"2022","journal-title":"Eur J Cancer"},{"key":"2026050103132342700_bib23","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1021\/acs.jmedchem.3c01622","article-title":"Design, synthesis, and biological evaluation of potent and selective PROTAC degraders of oncogenic KRASG12D","volume":"67","author":"Zhou","year":"2024","journal-title":"J Med Chem"},{"key":"2026050103132342700_bib24","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s41698-022-00329-w","article-title":"Co-targeting KRAS G12C and EGFR reduces both mutant and wild-type RAS-GTP","volume":"6","author":"McFall","year":"2022","journal-title":"NPJ Precis Oncol"},{"key":"2026050103132342700_bib25","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1158\/2159-8290.CD-22-1066","article-title":"Efficacy of a small-molecule inhibitor of KrasG12D in immunocompetent models of pancreatic cancer","volume":"13","author":"Kemp","year":"2023","journal-title":"Cancer Discov"},{"key":"2026050103132342700_bib26","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/j.ccell.2023.07.002","article-title":"KRASG12D inhibition reprograms the microenvironment of early and advanced pancreatic cancer to promote FAS-mediated killing by CD8+ T cells","volume":"41","author":"Mahadevan","year":"2023","journal-title":"Cancer Cell"},{"key":"2026050103132342700_bib27","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s40164-025-00637-4","article-title":"New exploration of KRASG12D inhibitors and the mechanisms of resistance","volume":"14","author":"Li","year":"2025","journal-title":"Exp Hematol Oncol"},{"key":"2026050103132342700_bib28","first-page":"391","article-title":"Glimmers of hope for targeting oncogenic KRAS-G12D","volume":"30","author":"Tang","year":"2023","journal-title":"Cancer Gene Ther"},{"key":"2026050103132342700_bib29","doi-asserted-by":"crossref","first-page":"1013902","DOI":"10.3389\/fonc.2022.1013902","article-title":"KRAS G12D targeted therapies for pancreatic cancer: has the fortress been conquered?","volume":"12","author":"Bannoura","year":"2022","journal-title":"Front Oncol"},{"issue":"8_Suppl_2","key":"2026050103132342700_bib30","doi-asserted-by":"crossref","first-page":"CT019","DOI":"10.1158\/1538-7445.AM2025-CT019","article-title":"Abstract CT019: preliminary safety and antitumor activity of zoldonrasib (RMC-9805), an oral, RAS(ON) G12D-selective, tri-complex inhibitor in patients with KRAS G12D non-small cell lung cancer (NSCLC) from a phase 1 study in advanced solid tumors","volume":"85","author":"Arbour","year":"2025","journal-title":"Cancer Res"},{"key":"2026050103132342700_bib31","doi-asserted-by":"crossref","first-page":"114980","DOI":"10.1016\/j.ejca.2024.114980","article-title":"502LBA LBA Orals: preliminary safety, pharmacokinetics, and antitumor activity of RMC-9805, an oral, RAS(ON) G12D-selective, tri-complex inhibitor in patients with KRAS G12D pancreatic ductal adenocarcinoma (PDAC) from a phase 1 study in advanced solid tumors","volume":"211","author":"Hong","year":"2024","journal-title":"Eur J Cancer"},{"key":"2026050103132342700_bib32","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.1016\/j.jtho.2025.09.110","article-title":"MA02.07 efficacy and safety of GFH375 in advanced non-small cell lung cancer patients with KRAS G12D mutation","volume":"20","author":"Lu","year":"2025","journal-title":"J Thorac Oncol"},{"issue":"Suppl 16","key":"2026050103132342700_bib33","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.1200\/JCO.2025.43.16_suppl.3013","article-title":"A first-in-human phase I\/II study of GFH375, a highly selective and potent oral KRAS G12D inhibitor in patients with KRAS G12D mutant advanced solid tumors","volume":"43","author":"Ai","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026050103132342700_bib34","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.annonc.2022.07.005","article-title":"Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRAS(G12D)-mutated non-small-cell lung cancer","volume":"33","author":"Ricciuti","year":"2022","journal-title":"Ann Oncol"},{"key":"2026050103132342700_bib35","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1002\/cac2.12327","article-title":"KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1\/PD-L1 immunotherapy in non-small cell lung cancer","volume":"42","author":"Liu","year":"2022","journal-title":"Cancer Commun (Lond)"}],"container-title":["Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/doi\/10.1158\/2159-8290.CD-25-1346\/3727313\/cd-25-1346.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/doi\/10.1158\/2159-8290.CD-25-1346\/3752709\/cd-25-1346.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/16\/5\/895\/3785909\/cd-25-1346.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/16\/5\/895\/3785909\/cd-25-1346.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T07:13:39Z","timestamp":1777619619000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/16\/5\/895\/784410\/Preclinical-Characterization-and-Clinical-Activity"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,21]]},"references-count":35,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,1,21]]},"published-print":{"date-parts":[[2026,5,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2159-8290.cd-25-1346","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2159-8290.32702389","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.32702386","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.32702392","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2159-8290.c.8542012","asserted-by":"object"}]},"ISSN":["2159-8274","2159-8290"],"issn-type":[{"value":"2159-8274","type":"print"},{"value":"2159-8290","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,21]]}}}